Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax®.

Symbyax® is marketed by Lilly USA and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of approximately $82 million in the United States, based on IMS sales data.

Source: Teva Pharmaceutical Industries Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
University students develop significant levels of anxiety or depression by the end of first year